LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Dec. 2, 2005--BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that BioSante has engaged Michael C. Snabes, M.D., Ph.D. as an independent consultant to work with BioSante’s current product development team in completion of certain Bio-E-Gel(TM) (bioidentical estradiol gel) new drug application (NDA) activities, as well as work on LibiGel(TM) (bioidentical testosterone gel) in development for the treatment of female sexual dysfunction. It is expected that BioSante’s Bio-E-Gel NDA will be filed with the U.S. Food and Drug Administration (FDA) in the first quarter 2006 and that Phase III clinical trials of LibiGel will be initiated in the same time period.
